Abstract
Using a monoclonal antibody against GPIb (TM60), we established an assay method for glycocalicin concentration in human plasma. The assay was based on the competitive inhibitory action of glycocalicin in plasma against TM60-binding to platelets. Washed human platelets (1.0×10) were adsorbed on the surface of an immunoplate using polylysine. Plasma was incubated with 4μg/ml of TM60 in the immunoplate. Amounts of bound TM60 on the platelets were measured by ELISA using peroxidase conjugated anti-mouse IgG. Plasma from normal volunteers contained 4.15±0.66 (n=13, mean±SD), while plasma from myeloproliferative disorders contained 5.15±0.63 (n=11, mean±SD). In the patient group, glycocalicin concentrations correlated with their platelet numbers in whole blood, suggesting that increases of glycocalicin in the patients were dependent on their platelet numbers.
